F-star Appoints Darlene Deptula-Hicks as Chief Financial Officer and Opens Office in Cambridge, MA
18.6.2019 14:00:00 EEST | Business Wire | Press release
F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy, today announces the appointment of Darlene Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga Hassan, who is appointed to serve as F-star’s Chief Operating Officer.
Darlene Deptula-Hicks joins F-star from Northern Biologics, Inc., a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody therapeutics in oncology. Previously, Darlene held CFO positions across both private and publicly listed US companies, including Pieris Pharmaceuticals Inc., Microline Surgical Inc. and T2 Biosystems Inc. She brings to F-star a proven track record of finance strategy and leadership, capital raising, industry knowledge and the ability to build strong strategic partnerships.
Darlene Deptula-Hicks, CFO of F-star, said: “It is a very exciting time to be joining F-star given its evolution to a fully-fledged clinical-stage, international business. The company’s pipeline of promising bispecific antibodies has the potential to address the growing need for, and commercial opportunity from, more efficacious therapies for cancer patients. I am excited to join the management team of this next-generation immunotherapy business.”
Eliot Forster, CEO of F-star, said: “We believe Darlene’s strong commercial and capital markets experience from within the life sciences sector will play a critical role in our transition and I’m delighted that she has joined the company. Tolga’s expertise and company knowledge continues to be vital to our success as we work towards realising our ambition to bring new drugs to cancer patients as quickly as we can.”
To support F-star’s international expansion strategy, the company has also established US operations based in Cambridge, MA. Research operations will continue at the company’s site in Cambridge, UK, while the US office will support the growth of F-star’s in-house financial, clinical and regulatory activities.
F-star has also appointed Lindsey Trickett as Vice President of Investor Relations and Communications. Lindsey brings with her a wealth of experience in investor relations and antibody drug development. She joins F-star from Intellia Therapeutics, Inc., where she served as a Vice President of Investor Relations. Previously, Lindsey held senior IR and strategic marketing positions at AstraZeneca plc and spent over a decade in roles of increasing responsibility at MedImmune, LLC/AstraZeneca plc.
Both Darlene and Lindsey will be based out of F-star’s US office.
- ENDS -
About F-star Therapeutics Ltd
F-star is a leading clinical-stage biopharmaceutical company delivering tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumour immune evasion, the Company’s goal is to offer patients greater and more durable benefits than current immuno-oncology treatments. Through its proprietary tetravalent, bispecific antibody (mAb²™) format, F-star is generating first- and best-in-class drug candidates with monoclonal antibody-like manufacturability. Building on the combined expertise of its world-class management team and scientific leadership, F-star is poised to deliver the next breakthrough immunotherapies for cancer patients.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190618005498/en/
Contact information
For investor enquiries:
Lindsey Trickett
VP
Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@f-star.com
Consilium
Strategic Communications
Chris Gardner, Sue Stuart, David Daley
Tel:
+44 (0)20 3709 5700
E-mail:
F-star@consilium-comms.com
For
media enquiries
Pierre Peotta
Communications Manager
+44
(0)1223 948 094
+44 (0)7392 080 279
pierre.peotta@f-star.com
US
Catherine
London, US President
Tel: +1 917-763-2709
E-mail: F-star@consilium-comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nanochon Receives Regulatory Approval from Panamá’s Ministry of Health to Initiate First-in-Human Clinical Study of Chondrograft™17.8.2026 22:44:00 EEST | Press release
Nanochon, a medical device company developing Chondrograft™, a novel patented implant for the treatment of articular cartilage defects of the knee, today announced that it has received regulatory approval from Panamá’s Ministry of Health to initiate its First-in-Human (FIH) clinical study in Panamá. The study will evaluate the safety and performance of Chondrograft™ in patients with focal chondral defects of the knee and represents a major milestone in the company’s clinical and regulatory development strategy. The trial will be conducted at The Panama Clinic in Panamá City under the leadership of Drs. Juan Osorio and Emilio Tufiño, experienced sports medicine surgeons, with Dr. Osorio serving as Principal Investigator for the study. Dr. Osorio stated, “I am pleased to be the Principal Investigator for this important study, and we look forward to contributing the data that will support a larger clinical study and subsequent market entry.” Nanochon selected Panamá for its growing reputa
TOURISE and Oxford Economics Release New Global Report on Tourism Resilience in an Era of Permanent Disruption17.8.2026 17:33:00 EEST | Press release
TOURISE, in collaboration with Oxford Economics, today released a new report, “Resilience in a World that Doesn’t Reset: Redesigning Tourism for an Era of Permanent Disruption.” The analysis of 85 major crises over two decades shows a clear pattern: in a world defined by continuous shocks, destinations that act before disruption hits recover up to 1.5 times faster than those that wait. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817880835/en/ “In a world that does not reset between crises, disruption is a constant feature of the global tourism landscape,” said His Excellency Ahmed Al-Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. “The real test for destinations measures how they prepare for volatility, protect traveler confidence, and maintain continuity ahead of such events.” Using the current Middle East crisis as a lens, where Gulf hubs carry roughly 14 percent of global transit traffic, the r
The Expensify Visa® Commercial Card Brings New Proactive Spend Controls to 14 Countries17.8.2026 16:00:00 EEST | Press release
Expensify, Inc. (Nasdaq: EXFY), the easiest way to manage expenses, travel, and corporate cards, today expanded the reach of Expensify Card spend rules, the market-leading way for businesses to control corporate card spend before it happens. Available to businesses in 14 countries, spend rules let admins decide exactly how, where, and when each Expensify Card can be used, so only compliant transactions go through. Unlike traditional corporate cards that rely on after-the-fact expense review, the Expensify Card enforces policy at the point of purchase. Admins set the rules once, and the card handles the rest. With Expensify Card spend rules, admins can: Lock a card to a subscription. Give each recurring SaaS tool its own virtual card, so a vendor can only ever charge what it should. If the card owner changes teams or leaves, the subscription keeps running, with no swapping cards and no missed payments. Cover a one-time purchase. Issue a virtual card for a single transaction like event r
Riskified Analysis Finds Travel Fraudsters Are Adapting Faster Than Traditional Signals Can Keep Up, With May Flight Risk Up 32%17.8.2026 15:30:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released new findings from its Travel Industry Insights report, revealing how sophisticated fraud rings and AI-enabled fraudsters are evolving their tactics across airlines, hotels, and online travel platforms. Riskified’s analysis shows that fraudsters are increasingly adapting their behavior to resemble legitimate travelers, making traditional fraud indicators less reliable and creating new challenges for travel merchants. Riskified’s analysis of hundreds of millions of travel transactions across flights, hotels, and land transportation found that flight fraud risk increased through the first five months of 2026, with May 2026 marking the sharpest year-over-year increase at 32% compared to May 2025. The findings show that sophisticated fraud activity is not limited to predictable travel peaks, with organized fraud rings continuously adjusting their methods throughout the year. Riskified's travel n
PIF Delivers Strong Revenue and Profit Growth in 202517.8.2026 14:54:00 EEST | Press release
PIF today published its 2025 Annual Report demonstrating strong financial performance and continued progress against its long-term objectives. As a long-term investor with a unique mandate to drive the economic transformation of Saudi Arabia and deliver sustainable financial returns, PIF maintained a diversified portfolio in 2025, balancing returns with national impact and long-term resilience. Maintaining Financial Discipline In 2025, revenue rose 9% year on year to $120 billion, while net profit more than doubled to $17 billion, supported by stronger contributions from maturing portfolio companies. PIF retained over $900 billion in assets under management and achieved an annualized total shareholder return of 5.8% since 2017. Total shareholder return in 2025 was positively driven by increased dividends from portfolio companies and returns from financial investments. It was also impacted by downward movements in the valuations of some assets, as a result of wider market conditions, an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom